Current Report Filing (8-k)
November 15 2021 - 08:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): November 12, 2021
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-54318
|
|
98-0573252
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
24
North Main Street
Pennington,
NJ 08534-2218
(Address
of Principal Executive Offices)
(855)
662-6732
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
ONCS
|
|
NASDAQ
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01.
|
Regulation
FD Disclosure
|
On
Friday, November 12, 2021, OncoSec Medical Incorporated (the “Company”) hosted a Key Opinion Leader Symposium via conference
call and webinar. The event provided a discussion on the clinical relevance of and updated data from the Company’s KEYNOTE-695
study of tavokinogene telseplasmid (“TAVO”), the Company’s lead product candidate, which was also presented in a poster
at the Society for Immunotherapy of Cancer 2021 Annual Meeting.
The
poster, PowerPoint slides, and other information presented, as well as a recording of the webinar, can be found on the Company’s
website at www.oncosec.com.
In
accordance with General Instruction B.2 of Form 8-K, the information disclosed in Item 7.01 of this Current Report on Form 8-K shall
not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated
by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein
is material.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ONCOSEC
MEDICAL INCORPORATED
|
|
(Registrant)
|
|
|
Date:
November 15, 2021
|
|
|
|
|
|
|
By:
|
/s/ Dr. Margaret Dalesandro
|
|
Name:
|
Dr. Margaret Dalesandro
|
|
Title:
|
Interim
Principal Executive Officer and Chair of the Board
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Feb 2024 to Mar 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2023 to Mar 2024